Validation of an IUS Activity Index (USE-IT)

Validation of an Intestinal Ultrasound Score Evaluating Inflammation and Treatment Response in Crohn's Disease (USE-IT): A Prospective Multicenter Study

The primary objective of this study is to prospectively validate a novel intestinal ultrasound (IUS) Crohn's disease (CD) activity index and component items, correlating CD activity and responsiveness to therapy as evaluated by IUS with evaluations by ileocolonoscopy (IC) (Simple Endoscopic Score for Crohn's disease [SES-CD]) and magnetic resonance enterography (MRE) (Simplified Magnetic Resonance Index of Activity [MaRIA] score).

Study Overview

• Status: Not yet recruiting
• Conditions: Crohn Disease
• Intervention / Treatment: Diagnostic test: Ultrasound, Colonoscopy, MRE

Detailed Description

Study Design Prospective multicenter study of 111 participants with CD with 50 weeks of follow-up Study Population Adult patients with moderately to severely active CD

Inclusion Criteria:

1. Confirmed diagnosis of CD according to standard clinical, endoscopic, and histologic criteria of at least 3 months duration
2. Adults 18 years of age or older

3. Moderate to severely active CD defined by:

   1. Active symptoms with a HBI ≥ 8, and
   2. Bowel wall inflammation defined as bowel wall thickness (BWT) > 3 mm in at least 1 segment of the ileum or colon as determined by IUS
4. Patients with planned introduction of biologic therapy as per their treating gastroenterologist to treat active disease
5. Written informed consent must be obtained and documented

Exclusion Criteria:

1. Patients with a primary diagnosis of ulcerative colitis or IBD type unclassified
2. Patients with prior intestinal surgery

3. Patients with disease-related structural bowel complications, defined as either:

   1. Stricture with increased bowel wall thickening (>25% of normal), decreased luminal diameter (≥ 50% relative to the normal adjacent bowel loop) and proximal dilation (on any imaging modality), or
   2. Penetrating complications (excluding perianal fistulizing disease; patients with perianal disease are eligible if there is additional inflammation in another bowel segment [other than the rectum])
4. Contraindication to IC or MRE
5. BMI greater than 35 at time of screening or other characteristics considered likely to preclude IUS visualization of all bowel segments
6. Disease limited to the rectum
7. Serious underlying disease other than CD that in the opinion of the investigator may interfere with the participant's ability to participate fully in the study
8. History of alcohol or drug abuse that in the opinion of the investigator may interfere with the participant's ability to comply with the study procedures
9. Pregnancy Data Sources and Data Collection Data will be collected from patient charts (paper or electronic) including medical and CD related history, medication records, and results of prior laboratory and imaging examinations. Patient disease-related outcomes including hospitalizations, emergency department (ED) visits, and surgeries will be collected during visits for analysis. Data will be transcribed from the patient's chart and entered into an electronic case report form by the investigator or authorized trained designee.

Questionnaires are to be completed by healthcare professionals and patients (i.e., baseline demographics, HRQoL ]SIBDQ], PRO-2, IBD Knowledge Questionnaire).

Outcomes

Primary Outcome:

• The longitudinal and construct validity and treatment responsiveness of an IUS CD activity index in an adult population with moderate to severely active CD

Secondary Outcomes:

• The correlation of IUS CD activity index and component items with IC
• The correlation of IUS CD activity index and component items with MRE
• The correlation of IUS CD activity index and component items with biomarkers
• The correlation of IUS CD activity index and component items with clinical activity scores
• The correlation of IUS CD activity index and component items with histology
• The correlation of IUS CD activity index and component items with HRQoL (SIBDQ) and PRO-2
• The proportion of patients with IUS response and transmural healing after initiation of a biologic therapy approved for CD
• The longitudinal validity of changes in IUS CD activity and component items after treatment with changes in IC, MRE, biomarkers, clinical disease activity scores, HRQoL (SIBDQ), PRO-2, and histology
• The correlation of terminal ileal small bowel peristalsis with IUS CD activity index and component items, MRE, and IC with CD activity
• The correlation of IUS CD activity index and component items with patient outcomes, including ED visitation, hospitalization, and surgery.

Statistical Methods Demographic and clinical data will be evaluated using descriptive statistics. A putative IUS CD activity index in development using at least moderately reliable (inter-rater ICC > 0.40) items from a prior study (Part I) and its component items will be evaluated in this prospective cohort study.

Sample Size:

Power calculations are based on the primary endpoint of IUS CD activity index responsiveness. Based on the variance formula for the standardized mean change, and assuming a correlation of 0.3 for baseline and follow-up scores, a sample size of 94 paired scores would have 80% power to detect a standardized mean change of 0.35. Accounting for 15% attrition, a sample size of 111 participants will be needed.

Outcome Analysis:

The primary aim of this study is to both establish IUS CD activity index responsiveness to effective medical therapy with demonstration of changes in activity over time as well as index external validation through correlation of individual IUS activity index components and overall score compared to both IC and MRE.

Similar correlations will be examined between the IUS CD activity index and HBI, GHAS, RHI, SIBDQ, PRO-2, transmural healing, terminal ileal small bowel peristalsis, and patient outcomes including ED visitation, hospitalization, and surgery. All participants in this prospective cohort will receive medical therapy of known efficacy for CD. The definition of change will be based on a global IUS measure of disease activity, quantified using a 100 mm visual analog scale (VAS), where 0 represents no disease activity and 100 represents the worst disease activity ever seen. Clinically meaningful change will be defined by a decrease of more than ½ the SD of the global IUS VAS at Baseline. Longitudinal validity will be correlated with changes in the IUS CD activity index and other measures of disease activity on IC, and changes in MRE (Simplified MaRIA score), HBI, CRP, and fCal. Responsiveness will be quantified using the standardized effect size (mean difference divided by SD) and the associated 95% CI, as well as the nonparametric probability for detecting change, expressed as the AUROC. Weighted correlation coefficients will be used to quantify longitudinal validity. An exploratory knowledge questionnaire (IBD Knowledge Questionnaire) will also be used to evaluate the evolution of patient IBD understanding through study participation. The potential for this study data to be applied in machine learning IUS diagnostics will also be considered.

Expected Impact Development of a reliable and responsive IUS CD activity index will improve standardization and consistency in IUS utilization globally. In the long-term, this can profoundly change the way in which IBD care is delivered, with wider adoption of repeatable accurate disease activity evaluation in clinic resulting in accelerated uptake of a treat-to-target strategy in CD. This strategy has been demonstrated to better inform clinical decision making, improve patient outcomes, and reduce long-term disability in patients with CD. In addition, an increased IUS uptake can engage patients to better understand their disease which will result in improved adherence to monitoring and treatment which will ultimately improve CD related outcomes.

• Study Type: Observational
• Enrollment (Anticipated): 110

Contacts and Locations

• Study Contact: Name: Jimmi Cording, PhD; Phone Number: 004915129110689; Email: jc@bowel-ultrasound.org
• Study Contact Backup: Name: Carmen Treubrodt; Phone Number: 00491744344130; Email: ct@bowel-ultrasound.org

Study Locations

• Germany
  • Berlin, Germany, 12161
    • IBUS office
    • Contact: Jimmi Cording, PhD; Phone Number: 004915129110689; Email: jc@bowel-ultrasound.org
    • Contact: Carmen Treubrodt; Phone Number: 00491744344130; Email: ct@bowel-ultrasound.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

This study is a multicenter, international, nonrandomized prospective cohort study across multiple sites in North America, Australia, and Europe.

The study population will consist of 111 adult participants with moderately to severely active CD managed as per SOC, in established IBD expert centers with access to IUS, IC, and MRE procedures.

Description

Inclusion Criteria:

1. Confirmed diagnosis of CD according to standard clinical, endoscopic, and histologic criteria of at least 3 months duration
2. Adults 18 years of age or older

3. Moderate to severely active CD defined by:

   1. Active symptoms with a HBI ≥ 8, and
   2. Bowel wall inflammation defined as BWT > 3 mm in at least 1 segment of the ileum or colon as determined by IUS
4. Patients with planned introduction of biologic therapy as per their treating gastroenterologist to treat active disease
5. Written informed consent must be obtained and documented.

Exclusion Criteria:

1. Patients with a primary diagnosis of ulcerative colitis or IBD type unclassified
2. Patients with prior intestinal surgery

3. Patients with disease-related structural bowel complications defined as either:

   1. Stricture with increased bowel wall thickening (>25% of normal), decreased luminal diameter (>50% relative to the normal adjacent bowel loop) and proximal dilation (on any imaging modality) or;
   2. Penetrating complications (excluding perianal fistulizing disease; patients with perianal disease are eligible if there is additional inflammation in another bowel segment [other than the rectum]).
4. Contraindication to IC or MRE
5. BMI greater than 35 at time of screening or other characteristics considered likely to preclude IUS visualization of all bowel segments
6. Disease limited to the rectum
7. Serious underlying disease other than CD that in the opinion of the investigator may interfere with the participant's ability to participate fully in the study
8. History of alcohol or drug abuse that in the opinion of the investigator may interfere with the participant's ability to comply with the study procedures
9. Pregnancy

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

Crohns disease patients; Adult patients with moderately to severely active CD

Diagnostic test: Ultrasound, Colonoscopy, MRE; After the initiation of an established treatment of known efficacy for CD (biologic agents including infliximab, adalimumab, ustekinumab or vedolizumab either with or without corticosteroids), repeat IC and MRE will occur at Week 30 (± 6 weeks) (6-9 months); the IUS, IC, and MRE examinations will occur within a 4-week window and with no intervening change in medical therapy. All imaging data will be captured electronically (IUS and MRE with Digital Imaging and Communications in Medicine [DICOM] images, and IC with video recordings) for central, blinded reading. Two biopsies will be collected from each segment of the bowel (rectum, sigmoid, descending, transverse, ascending and terminal ileum) during IC, fixed in formalin collection containers, and shipped for histopathology processing and evaluation.; Other Names: Collection of blood; Collection of Stuhl; Biopsie

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The longitudinal and construct validity and treatment responsiveness of an IUS CD activity index in an adult population with moderate to severely active CD	The newly formed activity index determined by intestinal ultrasound is compared with the results of colonoscopy (IC), MRE, blood and stool markers.	week 0 to week 50

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The correlation of IUS CD activity index and component items with IC	Disease activity determined by intestinal ultrasound is compared with the results of colonoscopy (IC) examinations.	week 0 to week 50
The correlation of IUS CD activity index and component items with MRE	Disease activity determined by intestinal ultrasound is compared with the results of MRE examinations.	week 0 to week 50
The correlation of IUS CD activity index and component items with biomarkers	Disease activity determined by intestinal ultrasound is compared with the results of Biomarker analysis.	week 0 to week 50
The correlation of IUS CD activity index and component items with histology		week 0 to week 50
The correlation of IUS CD activity index and component items with HRQoL (SIBDQ) and PRO-2	Disease activity determined by intestinal ultrasound is compared with the results of patient-reported outcomes HRQoL (SIBDQ) and PRO-2.	week 0 to week 50

Collaborators and Investigators

• Sponsor: International Bowel Ultrasound Group e.V.
• Investigators: Principal Investigator: Kerri Novak, Prof, University of Calgary

Study record dates

Study Major Dates

• Study Start (Anticipated): June 1, 2022
• Primary Completion (Anticipated): June 1, 2024
• Study Completion (Anticipated): June 1, 2025

Study Registration Dates

• First Submitted: April 25, 2022
• First Submitted That Met QC Criteria: June 2, 2022
• First Posted (Actual): June 7, 2022

Study Record Updates

• Last Update Posted (Actual): June 7, 2022
• Last Update Submitted That Met QC Criteria: June 2, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Keywords: Colonoscopy; MRE; intestinal ultrasound
• Additional Relevant MeSH Terms: Digestive System Diseases; Gastrointestinal Diseases; Gastroenteritis; Intestinal Diseases; Inflammatory Bowel Diseases; Crohn Disease
• Other Study ID Numbers: USE-IT-01434

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No